(USD) | Mar 2023 | Q/Q |
---|---|---|
Revenue | 550K | - |
Operating Income | -5MM | -3% |
Operating Expenses | 5.5MM | - |
Net Income | - | - |
R&D | 3.8MM | +2% |
G&A | 1.7MM | +8% |
Interest Expense | 0 | -100% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted b
Point72 Asset Management, led by renowned investor Steven Cohen (Trades, Portfolio), has recently initiated a position in Vaccinex Inc (NASDAQ:VCNX), a biotechnology company focused on cancer and neurodegenerative disease treatment. On February 6, 2024, the firm acquired 1,631,648 shares of Vaccinex Inc, marking a new holding in its investment portfolio. The shares were purchased at a price of $0.5863 each, reflecting a significant move by the firm into the biotech sector.
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, includin
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer, previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in comp
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial r
Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanomaROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two presentations at the 38th Annual Meeting of the Society for Immunotherapy
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient bloodROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, MA. Vaccinex has previously re
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced it has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company’s Board of Direct